A process for producing a glycoprotein composition improved in the amount of sialic acid added to the sugar chain; a method of culturing a cell producing a glycoprotein composition improved in the amount of sialic acid added to the sugar chain; a method of improving the amount of sialic acid to be added to the sugar chain of a glycoprotein composition; and a method of reducing the content of N-glycolylneuraminic acid in a glycoprotein composition.
It is intended to provide: a method of culturing animal cells capable of producing a substance characterized in that, in the method of culturing animal cells capable of producing the substance, the culture is conducted by adding a dipeptide; a method of producing a substance characterized in that, in the method of producing the substance by culturing animal cells capable of producing the substance, the culture is conducted by adding a dipeptide and the substance thus formed and accumulated in the culture medium is harvested from the culture; a method of elevating the productivity per cell of a substance produced by animal cells capable of producing the substance characterized in that the cells are cultured by adding a dipeptide; a method of sustaining the survival rate of animal cells capable of producing a substance characterized in that the cells are cultured by adding a dipeptide; a method of inhibiting an increase in ammonium ion concentration of a liquid culture medium of animal cells capable of producing a substance characterized in that the cells are cultured by adding a dipeptide; and a method of inhibiting apoptosis of animal cells capable of producing a substance characterized in that the cells are cultured by adding a dipeptide.
An isoquinoline derivative represented by the formula (I), a pharmaceutically acceptable salt thereof or the like which has an inhibitory activity on p38 mitogen-activated protein (p38MAP) kinase [in the formula, represents a single bond or a double bond; R1 represents an aryl which may have a substituent, an aromatic heterocyclic group which may have a substituent, or the like; R2 represents an aryl which may have a substituent, an aromatic heterocyclic group which may have a substituent, or the like; R4 represents X-R6 [wherein X represents a bond, an oxygen atom, NR7 (where R7 represents a hydrogen atom, a lower alkyl which may have a substituent, or the like), or the like] or the like; and R6 represents a hydrogen atom, a lower alkyl which may have a substituent, an alicyclic heterocyclic group which may have a substituent, or the like]; R3 and R5 independently represent a hydrogen atom, a lower alkyl group, or the like; and n represents a number of 0 or 1, provided that all of R2, R3, R4 and R5 do not represent a hydrogen atom in the molecule].
C07D 217/14 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
A61P 5/38 - Drugs for disorders of the endocrine system of the suprarenal hormones
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
4.
AGENT FOR AMELIORATING THE CONDITION OF SICK BUILDING SYNDROME
Disclosed is a safe and highly effective agent for ameliorating the condition of sick building syndrome. The agent comprises a plant belonging to the genus Matricaria or Anthemis or an extract from the plant as an active ingredient.
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
Disclosed are: a polypeptide derived from an adult cat flea; DNA encoding the polypeptide; an antibody capable of recognizing the polypeptide; a monoclonal antibody capable of killing an adult cat flea; a vaccine for killing an adult cat flea, which comprises, as an active ingredient, a polypeptide having an epitope site which can be recognized by the monoclonal antibody; and an inhibitor of the multiplication of an adult cat flea or an agent for killing an adult cat flea, which comprises the monoclonal antibody as an active ingredient.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Disclosed is a process for separation and purification of ornithine or arginine from a culture containing the amino acid. According to the process, ornithine or arginine can be separate and purified by applying a culture containing ornithine or arginine and a microorganism cell onto the top part of a column packed with a particulate carrier having a particle diameter of 350 &mgr;m or more and capable of adsorbing ornithine or arginine thereon, and then applying an eluent to the column.
A bowel movement remedy that for persons with the symptoms of firm stool, having a difficult bowel movement, poor stool frequency/quantity, etc., relieves the symptoms and allows them to have a healthy life. There is provided a bowel movement remedy comprising alanylglutamine or its salt as an active ingredient.
A wake-up remedy that for persons with the subjective symptoms of feeling languid after wake-up, having a hard time awaking, etc., relieves the symptoms and allows them to have a fulfilling life. There is provided a wake-up remedy comprising alanylglutamine or its salt as an active ingredient.
Disclosed is a process for separation and purification of histidine from a culture containing the amino acid. According to the process, histidine can be separated and purified by applying a culture containing histidine and a microorganism cell onto the top part of a column packed with a particulate carrier having a particle diameter of 350 &mgr;m or more and capable of adsorbing histidine thereon, and then applying an eluent to the column. In the process, it is preferred to use a strongly acidic cation exchange resin as the particulate carrier.
It is intended to provide a low calorie sweetener excellent in safety and sweetness. According to the invention, the sweetener containing as an active ingredient a dipeptide selected from the group consisting of alanyl tryptophan, valyl tryptophan, lysyl tryptophan, arginyl tryptophan, arginyl tyrosine and lysyl alanine, or a salt thereof can be provided.
A23K 1/16 - supplemented with accessory food factors; Salt blocks
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
C07K 5/068 - Dipeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
11.
ORAL AGENT FOR PROMOTING SYNTHESIS OF TISSUE COLLAGEN
Disclosed is: an oral agent for promoting the synthesis of tissue collagen; an oral agent for promoting the healing of a wound on the skin; or an oral agent for preventing or ameliorating skin wrinkles or sags, which is safe, has excellent effect, and comprises hydroxyproline or a salt thereof as an active ingredient.
A muscle fatigue remedy that for persons with the symptoms of muscle pain attributed to strenuous exercise, lassitude in the arms and legs attributed to quick exercise, low back pain and stiffness in the shoulder attributed to taking of a certain posture over a prolonged period of time, etc., relieves the symptoms and allows them to have a fulfilling life. There is provided a muscle fatigue remedy comprising alanylglutamine or its salt as an active ingredient.
Disclosed is an anti-cytoplasmic sialidase monoclonal antibody which can recognize the conformation of a mammal-derived cytoplasmic sialidase and can neutralize the activity of a mammal-derived cytoplasmic sialidase. Also disclosed is a method for producing a glycoprotein composition which has a sugar chain having sialic acid added thereto, by using the antibody.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C07K 2/00 - Peptides of undefined number of amino acidsDerivatives thereof
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
Disclosed is a safe and highly effective insulin resistance-improving agent or hyperinsulinism-ameliorating agent. The insulin resistance-improving agent or hyperinsulinism-ameliorating agent comprises hydroxyproline, an N-acylated derivative of hydroxyproline or a salt of hydroxyproline or the N-acylated derivative and a biguanide as active ingredients.
Disclosed is a process for separation and purification of a hydrophobic amino acid selected from the group consisting of alanine, leucine, valine, isoleucine, phenylalanine and proline or a neutral polar amino acid selected from the group consisting of serine, glycine, asparagine and glutamine from a culture containing the amino acid. The process comprises applying a culture containing the hydrophobic amino acid or the neutral polar amino acid and a microorganism cell onto the top part of a column packed with a particulate carrier having a particle diameter of 350 &mgr;m or more and capable of adsorbing the amino acid thereon, and then applying an eluent to the column.
Disclosed is a method for separating and purifying a nucleoside or nucleotide from a culture solution containing the nucleoside or nucleotide. The method comprises the steps of: applying a culture solution containing a nucleoside or nucleotide and a microorganism cell onto the top part of a column packed with a particulate carrier having a particle diameter of 350 &mgr;m or greater and capable of adsorbing the nucleoside or nucleotide and passing the culture solution through the column; and passing an eluent through the column, thereby separating and purifying the nucleoside or nucleotide.
Disclosed is a method for separating and purifying a basic amino acid, preferably a basic amino acid selected from arginine, lysine and ornithine, from a culture solution containing the amino acid. The method comprises the steps of: applying a culture solution containing a basic amino acid and a microorganism cell, preferably adjusted to pH 4 to 10, onto the top part of a column packed with a weakly acidic cation exchange resin having a particle diameter of 300 &mgr;m or greater and passing the culture solution through the column; and applying an eluent onto the top part of the column and passing the eluent through the column, thereby separating and purifying the basic amino acid.
Disclosed is a therapeutic agent for food intake disorder or water intake disorder, which comprises a peptide having an activity of stimulating the food intake behavior or water intake behavior as an active ingredient. Also disclosed is a method for screening a substance capable of enhancing or inhibiting the activity of the peptide by using the peptide.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
It has been demanded to provide a glycoprotein composition having a high physiological activity by increasing the addition amount of sialic acid in the glycoprotein composition. According to the invention, a cell in which siRNA which suppresses a sialidase activity is introduced or expressed, a method for producing a glycoprotein molecule using the cell, and a glycoprotein composition obtained by the production method are provided.
Disclosed is a mutant of an enzyme involved in such a sugar chain modification that an α-bonding is formed between position-6 of N-acetylglycosamine at the reducing terminus of a N-glycoside-bound composite sugar chain and position-1 of fucose, wherein the mutant has such an amino acid modification that the enzymatic activity is deleted or reduced. Also disclosed is use of the mutant.
Disclosed is a non-human animal which has the tissue-specific reduction or defect in the activity of an enzyme involved in a sugar chain modification, wherein the sugar chain modification is characterized in that an α-bonding is formed between position-6 of N-acetylglycosamine at the reducing terminus of a N-glycoside-bound composite sugar chain and position-1 of fucose. Also disclosed is a method for production of the non-human animal. Further disclosed is use of the non-human animal.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
A01K 67/027 - New or modified breeds of vertebrates
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
It is intended to provide a composition which contains a liposome having an RNA enclosed therein, wherein the RNA contains a sequence consisting of 15 to 30 consecutive bases in mRNA of a target gene relating to a disease in the eyeball and a sequence complementary to the above-described sequence, and by which the liposome reaches to the eyeball. The liposome having the RNA enclosed therein is a liposome comprising, for example, a complex particle composed of a lead particle containing a cationic lipid and a particle having the RNA as the constituents thereof and a bimolecular lipid membrane coating the complex particle. The bimolecular lipid membrane is a bimolecular lipid membrane having a neutral lipid, a lipid derivative of a water-soluble substance, a fatty acid derivative or an aliphatic hydrocarbon derivative as the constituents.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
It is intended to provide a muscle-building agent by which muscles can be increased without loading exercise stress by a special exercise such as resistance exercise. Namely, a muscle-building agent, which is characterized by containing ornithine or its salt as the active ingredient and being capable of increasing muscles without loading exercise stress by resistance exercise, can be provided.
Disclosed are: a protein having a dipeptide-synthesizing activity; DNA encoding the protein; recombinant DNA carrying the DNA; a transformant transformed with the recombinant DNA; a method for production of a protein having a dipeptide-synthesizing activity by using the transformant or the like; a method for production of a dipeptide by using a protein having a dipeptide-synthesizing activity; and a method for production of a dipeptide by using a culture of a transformant or microorganism capable of producing a protein having a dipeptide-synthesizing activity or the like as an enzyme source.
Disclosed are: a polypeptide which is characterized in that the polypeptide comprises an amino acid sequence having the deletion, substitution or addition of at least one amino acid residue in the amino acid sequence for glutamine synthetase 2 derived from a microorganism belonging to the genus Corynebacterium, and that a Corynebacterium capable of producing the polypeptide can produce L-glutamine; DNA encoding the polypeptide; recombinant DNA carrying the DNA; a microorganism harboring the DNA or the recombinant DNA; and a method for production of L-glutamine using the microorganism.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
It is intended to provide an easily absorbed oral preparation containing a xanthine derivative which exhibits adenosine A1 receptor antagonism and has a diuretic action, a renoprotective action, a bronchodilator action, an action of improving brain function, an anti-dementia action and the like, in which the xanthine derivative is dissolved in a solvent thereby improving its absorbability, and the easily absorbed oral preparation containing the xanthine derivative or a pharmaceutically acceptable salt thereof and a fatty acid or a fatty acid derivative is provided.
It is intended to provide a protein having a peptide synthesis activity, a DNA encoding this protein, a recombinant DNA containing the above DNA, a transformant having been transformed by this recombinant DNA, a process for producing a protein having a peptide synthesis activity by using the above transformant, a process for producing a peptide by using the above protein, and a process for producing a peptide by using a transformant producing the above protein, a microbial culture or the like as an enzyme source.
It is intended to provide an oral preparation for preventing or improving skin dryness accompanying atopic dermatitis, xeroderma, rough hands, rough skin, or the like. According to the invention, the oral preparation for preventing or improving skin dryness comprising citrulline or a salt thereof as an active ingredient can be provided.
JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CANCER CENTER (Japan)
Inventor
Ochiai, Atsushi
Hosaka, Emi
Nakamura, Kazuyasu
Furuya, Akiko
Ohki, Yuji
Abstract
It has been demanded to develop an antibody capable of binding to a polypeptide encoded by a human PERP (p53 apoptosis effector related to PMP-22) gene which is believed to be involved in the development of cancer or the like. Thus, disclosed is a genetically recombinant antibody which has a variable region bearing no consensus sequence to which an N-binding sugar chain can be bound, can recognize specifically the conformation of an extracellular region of a polypeptide encoded by the PERP gene, and can bind to the extracellular region. The antibody is useful for the treatment of various diseases in which a polypeptide encoded by the PERP gene is expresses.
An industrially advantageous process for producing a compound capable of inhibiting an HMG-CoA reductase and having an activity of decreasing the serum cholesterol level, which is characterized by using a protein comprising an amino acid sequence depicted in any one of SEQ ID NOs:1-3 (provided that, a protein comprising an amino acid sequence depicted in any one of SEQ ID NOs:4-6 is excluded) and DNA encoding a protein comprising an amino acid sequence depicted in any one of SEQ ID NOs:1-3 (provided that, DNA encoding a protein comprising an amino acid sequence depicted in SEQ ID NO:4 is excluded).
patents
